Insilico Medicine

by Insilico Medicine  · Based in United States → — Generative AI Software for Drug Discovery, Scientific Research & Sustainability
Oncology
Website Contact
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Insilico Medicine offers a suite of AI tools, collectively known as Pharma.ai, designed to accelerate various stages of drug discovery and development. These tools are primarily for researchers in pharmaceutical companies, biotechnology firms, and academic institutions involved in drug discovery, medicinal chemistry, and preclinical development.

  • PandaOmics: This tool focuses on target discovery, utilizing AI to identify potential disease targets. It is intended for researchers in early-stage drug discovery to pinpoint promising biological targets for therapeutic intervention.
  • Chemistry42: This platform is designed for generative chemistry, enabling the design and optimization of novel molecules. It assists medicinal chemists in generating new chemical entities with desired properties, streamlining the hit-to-lead and lead optimization phases.
  • Generative Biologics: This tool supports the design of biologics, such as antibodies and proteins. It is for researchers working on large molecule therapeutics, aiding in the creation of biologics with improved efficacy and safety profiles.
  • inClinico: This component focuses on predicting clinical trial outcomes. It is intended for clinical development teams to assess the likelihood of success for drug candidates in clinical trials, potentially informing go/no-go decisions.
  • Science42: DORA: This tool acts as an AI-powered assistant for scientific literature review and data analysis. It helps researchers efficiently extract and synthesize information from scientific publications, supporting various research activities from target identification to preclinical study design.

These tools integrate into the drug discovery workflow by automating and augmenting tasks that traditionally require significant manual effort and time, from identifying disease targets and designing molecules to predicting clinical outcomes. The suite aims to reduce the overall time and cost associated with bringing new drugs to market.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Pharma.ai Suite
  • PandaOmics (Target Discovery)
  • Chemistry42 (Generative Chemistry)
  • Generative Biologics (Biologics Design)
  • inClinico (Clinical Development Support)
  • Science42: DORA (Preclinical Development)
  • Large Language of Life Models (LLLMs)
  • AI-driven drug discovery pipeline
  • Disease Modeling
  • Automated Drug Development

Use Cases

  • Target identification and validation
  • Novel molecule generation
  • Lead optimization
  • Preclinical development support
  • Clinical trial design assistance
  • Therapeutic program discovery for various diseases

What Physicians Need to Know

Molecule Screening Capability
Insilico Medicine's Chemistry42 engine utilizes generative AI to design novel drug candidates from scratch, producing drug-like molecular structures with optimized physicochemical properties. It can generate over 2,400 molecule candidates within dozens of hours by combining generative AI and physics-based methods. The platform encompasses molecular generation, free energy binding prediction, ADMET property prediction, kinase selectivity prediction, and retrosynthesis route screening.
Clinical Trial Matching
While not a direct 'matching' service, Insilico's InClinico platform predicts clinical trial outcomes and enhances trial design by analyzing protocol details. It uses AI models to identify patient subgroups most likely to respond to specific treatments, which can indirectly aid in patient stratification for clinical trials.
Real-World Evidence Analysis
Insilico Medicine is recognized for its AI-enabled Real-World Evidence (RWE) platforms, which integrate clinical, genomic, and phenotypic datasets to uncover disease mechanisms and biomarkers, accelerating early discovery and supporting precision drug design. RWE is utilized to validate AI-generated drug-repositioning candidates through retrospective assessment of drug efficacy using Electronic Health Records and insurance databases.
Genomic Data Integration
The PandaOmics platform integrates 22 multi-modal data sources, including genomics, transcriptomics, proteomics, pathways, clinical trial records, and scientific literature, to create disease-specific models for target identification. It aggregates diverse datasets such as gene expression, proteomics, and methylation, employing 23 disease-specific machine learning models. The Pharma.AI platform leverages millions of data samples and multiple data types to discover disease biomarkers and identify promising targets.
Literature Mining
PandaOmics incorporates literature mining and knowledge graphs to link genes to mechanisms, extensively referencing scientific literature and grant descriptions for text evidence prioritization. It combines omics data with prior information from publications, clinical trials, and grant applications. The InClinico platform also utilizes 30 million publications as a data source.
Target Identification
Insilico's PandaOmics is an AI-powered discovery engine that rapidly identifies and prioritizes therapeutic targets and biomarkers using deep learning algorithms and multi-omics data. Its TargetPro model integrates 22 multi-modal data sources to identify targets with a high likelihood of clinical success, achieving 71.6% retrieval of known clinical targets and demonstrating high druggability and repurposing potential for novel targets. The platform considers novelty, confidence, commercial tractability, druggability, and safety in its prioritization.
Safety Signal Detection
While a dedicated tool isn't explicitly named, Insilico's platforms contribute to drug safety by incorporating 'safety' as a criterion in target prioritization (PandaOmics). The broader application of AI in pharmacovigilance, including proactive signal detection leveraging real-world data and advanced analytics from various sources like spontaneous reporting systems and medical literature, is a relevant area for in-silico approaches.
Collaboration Features
Insilico Medicine actively engages in R&D collaborations with major pharmaceutical companies, including Sanofi, Fosun Pharma, Eli Lilly, The Menarini Group, Stemline Therapeutics, Taisho, Astellas, Boehringer Ingelheim, and Pfizer. They have also launched an Automated AI-Driven Partnering System to streamline business development, manage due diligence, and scale partnerships more efficiently.
Publication Support
Insilico Medicine offers an AI assistant named DORA (Science42: DORA) designed to aid in drafting medical research papers, academic papers, case studies, and applications for grants and patents. DORA leverages multiple AI and large language models, featuring enhanced reasoning capabilities and real-time content verification. Insilico itself has a robust publication record, with over 200 peer-reviewed papers, including six in Nature portfolios since 2024.
Physician Tip

Physicians can leverage Insilico Medicine's AI tools to gain deeper insights into disease mechanisms and identify potential novel drug targets, which could inform future therapeutic strategies. The integration of multi-omics and real-world data offers a comprehensive view of patient biology, potentially leading to more personalized treatment approaches. For researchers, the AI-powered publication support tool (DORA) can significantly streamline the process of drafting and disseminating research findings, grants, and patents, enhancing productivity and knowledge sharing.

Insilico Medicine's Pharma.AI platform is built on Amazon Web Services (AWS) and their Nach01 multimodal foundation model is demonstrated on Microsoft Discovery, leveraging a secure Azure environment for AI-native drug discovery workflows. The platform integrates with a vast array of data sources, including genomics, transcriptomics, proteomics, pathways, clinical trial records, scientific literature, grants, and patents. Furthermore, Insilico collaborates with NVIDIA, utilizing NVIDIA Tensor Core GPUs in their Chemistry42 engine and NVIDIA BioNeMo to accelerate early drug discovery. The MMAI Gym for Science provides a comprehensive training platform with over 1,000 pharmaceutical benchmarks.

Details

Category Drug Discovery & Research
Pricing Contact for pricing
  • Insilico Medicine generates revenue from research and development collaborations with pharmaceutical companies and subscription fees for its generative AI platforms
  • Pricing for collaborations and licensing deals can range from hundreds of thousands to millions of dollars annually, including upfront payments, research funding, milestone payments, and royalties on future sales
  • The Nach01 model is available on AWS Marketplace and Microsoft Discovery platform
  • DORA Community Edition is free and self-hostable, while DORA SaaS offers advanced features and access to Insilico's data warehouse
Free TrialUnknown
DeploymentCloud
Mobile AppNone
API AvailableUnknown
Data ExportUnknown
TrainingUnknown
Target Sizeenterprise
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Insilico Medicine has received multiple Investigational New Drug (IND) clearances from the FDA for its AI-designed drug candidates, allowing them to enter clinical trials. Notable clearances include ISM5939 (ENPP1 inhibitor for solid tumors), ISM8969 (NLRP3 inhibitor for Parkinson's Disease), ISM3412 (MAT2A inhibitor for MTAP deleted cancers), and Rentosertib (for idiopathic pulmonary fibrosis).
GDPRUnknown AI-estimated
Integrations
EHR Not specified
Specialties Oncology

Social Proof

Customersunknown

Support & Reliability

Training ProvidedUnknown

What the Web Says

Insilico Medicine is a biotechnology company that utilizes AI platforms for drug discovery and development, aiming to significantly reduce the time and cost associated with bringing new medications to market. Their end-to-end AI engine, Pharma.AI, includes platforms like PandaOmics for target identification and Chemistry42 for de novo molecule generation. The company has successfully advanced AI-designed molecules into clinical trials, demonstrating the potential of their approach to accelerate drug pipelines.

Overall: Mixed

Strengths

  • Accelerated drug development process, reducing timelines significantly (e.g., from target discovery to compound validation in under 18 months).
  • Reduced average drug discovery costs by over $650 million in some cases.
  • Ability to identify novel biological targets and design new molecular structures that human chemists might not consider, offering patent advantages.
  • Democratizes access to sophisticated bioinformatics and computational tools for drug discovery.
  • Multiple drug programs are in various stages of preclinical and clinical development, with some candidates reaching Phase II clinical trials.
  • Strong emphasis on generative AI across both biology (target ID) and chemistry (molecule design).

Limitations

  • Employee reviews on platforms like Indeed indicate significant issues with management, work-life balance, pay and benefits, and company culture, describing leadership as authoritarian and hostile.
  • The platform is enterprise-level biotech infrastructure, making it inaccessible to smaller players or individual researchers due to its business model and custom pricing.
  • All programs are still in clinical testing with no approved drugs yet, meaning the platform's true value will only be clear with demonstrated clinical benefit at scale.
  • The efficacy of AI models is heavily reliant on the quality and quantity of training data, and biases or gaps in this data could affect predictions.
  • Experimental validation in wet labs and clinical trials remains crucial despite advanced in silico predictions.
  • In silico screening, while cheap and easy, may not always pan out to actual efficacy, with some experts suggesting taking such data with a grain of salt due to unaccounted variables.

Based on reviews from: Indeed.com, AWS, Trustpilot, Deep Pharma Intelligence, Reddit, Insilico Medicine (Official Website), AI tool (Review Site), Health Technology Assessment for In Silico Medicine: Social, Ethical and Legal Aspects (Research Paper), HealthyData, CompareThe.AI, Vaight AI

Last updated: 2026-08-11

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Insilico Medicine

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Insilico Medicine Press Release
Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
Insilico Medicine has nominated ISM9077, an AI-empowered, potential first-in-class Target Y inhibitor, as a Preclinical Candidate for ocular diseases, inflammatory disorders, and aging, demonstrating superior efficacy in preclinical models.
2026-08
Forbes
How Insilico Medicine Is Using AI To Reinvent Drug Discovery
Insilico Medicine is leveraging generative AI to revolutionize drug discovery, having successfully designed an AI-created drug candidate that reached Phase 2 clinical trials in under 18 months.
2026-08
Insilico Medicine Press Release
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
Insilico Medicine's ISM6331, an AI-driven pan-TEAD inhibitor, has received FDA Fast Track Designation for treating advanced mesothelioma, aiming to accelerate its clinical development.
2026-07
News-Medical.net
Insilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer
Insilico Medicine published a study in npj Precision Oncology demonstrating how AI and multi-omic analysis can identify therapeutic targets for rare sinonasal squamous cell carcinoma.
2026-08
EurekAlert!
Insilico Medicine releases positive profit alert for the first half of 2026
Insilico Medicine announced a positive profit alert for the first half of 2026, projecting significant revenue growth and net profit, driven by sustained revenue and improved operational efficiency.
2026-07
Insilico Medicine Press Release
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance to combine Insilico's AI platform with Bora's development and manufacturing expertise, aiming to integrate AI across the entire drug development value chain.
2026-07
PharmExec
Insilico Medicine and CMS Enter $177 Million AI-Powered Drug Discovery Collaboration
Insilico Medicine and China Medical System Holdings (CMS) have expanded their partnership with a second CNS-focused collaboration, a deal potentially worth up to $177 million in milestones.
2026-07
PR Newswire
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
Insilico Medicine and Human Longevity, Inc. are collaborating to develop the industry's first large-scale AI foundation model for longevity science, aiming to decode aging mechanisms and enable predictive healthcare.
2026-05

Videos

Product demos, reviews, and walkthroughs for Insilico Medicine.

View all on YouTube

Frequently Asked Questions

Insilico Medicine's Pharma.AI platform leverages generative AI across biology (PandaOmics), chemistry (Chemistry42), and clinical development (inClinico) to accelerate drug discovery. It identifies novel disease targets, designs new molecular structures with desired properties, and predicts clinical trial outcomes, significantly reducing the time and cost compared to traditional methods.
The deployment of AI in drug development introduces complex legal and regulatory challenges, including compliance with evolving frameworks and ensuring intellectual property protection. Regulatory agencies like the FDA and EMA are developing guidance, and Insilico Medicine's AI-discovered drugs, such as their lead fibrosis candidate, have progressed through clinical trials, demonstrating their ability to navigate these pathways.
Alternatives include traditional, labor-intensive drug discovery methods, which typically take longer and are more expensive. Other AI-driven drug discovery companies like Exscientia and BenevolentAI also exist, each with their own platforms and focus areas, offering different approaches to leveraging AI in the pharmaceutical space.
Insilico Medicine claims its AI platform can advance from target identification to clinical candidate nomination in less than 18 months at approximately 10% of conventional costs. Traditional drug discovery can take 10-15 years and billions of dollars, making AI a significantly faster and more cost-efficient approach for early-stage development.
Despite advancements, challenges in AI drug discovery include data quality, model interpretability, and navigating evolving regulatory hurdles. While AI accelerates preclinical development, clinical success is not guaranteed, and a hybrid human-AI approach remains crucial for integrating AI effectively into drug discovery workflows.
Insilico Medicine has a diversified pipeline with programs spanning multiple therapeutic areas, including fibrosis, oncology, immunology, metabolic diseases, and aging-related conditions. Their lead drug candidate, INS018_055, an AI-discovered and designed small molecule, is currently in Phase II clinical trials for idiopathic pulmonary fibrosis.

Related Tools

Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.
Free
Trially AI
Trially AI
Drug Discovery & Research
Trially's HIPAA-compliant AI platform matches, engages, and enrolls patients into trials with high accuracy, built for physicians and research sites.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.
Mendel.ai
Mendel.ai
Clinical Decision Support & Reference
Mendel.ai uses Neuro-Symbolic AI to sort patient cohorts from EHRs for clinical trial matching, accelerating research.
Contact for pricing
Haystack Enroll
Haystack Health
Drug Discovery & Research
Haystack Health is a clinical trial platform that utilizes AI and care navigation to connect health plan members and ACO patients with relevant clinical trials, aiming to expand treatment access and improve outcomes.
Custom quote
Dyania Health Clinical Trial Recruitment
Dyania Health
Drug Discovery & Research
Dyania Health's AI-powered software automates patient identification from EHRs for clinical trial recruitment, serving hospitals, health systems, and pharmaceutical companies.

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-07-03 | First Added: 2026-05-10

Investors who backed Insilico Medicine

Funded through the company that built this tool.

Prosperity7 Ventures
Corporate VC AI T2
Dhahran, Saudi Arabia
$5M-$25M
Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, headquartered in Dhahran, Saudi Arabia, with approximately $3 billion AUM deploying $5M-$25M…
AI/ML in Healthcare Digital Health
AI Tool Finder
AI-powered search. Results may not be comprehensive.